Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D MARTIN

Showing results (131-140 of 133) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 133 results.
Journal of Vascular Surgery|January 22, 2000
Endovascular-assisted versus conventional in situ saphenous vein bypass grafting: cumulative patency, limb salvage, and cost results in a 39-month multicenter studyD Rosenthal, E J Arous, S G Friedman, et al.
The Review of Scientific Instruments|October 7, 2025
Novel application of neutrinos to evaluate U.S. nuclear weapons performanceJ R Distel, E C Dunton, J M Durham, et al.
Nature|September 28, 1999
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14R S Ames, H M Sarau, J K Chambers, et al.
Pageof 14

Showing results (131-140 of 133) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 133 results.
Journal of Vascular Surgery|January 22, 2000
Endovascular-assisted versus conventional in situ saphenous vein bypass grafting: cumulative patency, limb salvage, and cost results in a 39-month multicenter studyD Rosenthal, E J Arous, S G Friedman, et al.
The Review of Scientific Instruments|October 7, 2025
Novel application of neutrinos to evaluate U.S. nuclear weapons performanceJ R Distel, E C Dunton, J M Durham, et al.
Nature|September 28, 1999
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14R S Ames, H M Sarau, J K Chambers, et al.
Pageof 14